Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE12.9500
- TODAY'S CHANGE (%)0.1300 (1.0140%)
- Bid / Lots5.1000/ 2
- Ask / Lots15.5000/ 4
- Open / Previous Close12.9600 / 12.8200
- Day Range
- 52 Week Range
- Volume176,010
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 1628 | 12.8 |
| 09:36 ET | 300 | 12.88 |
| 09:43 ET | 1203 | 13.07 |
| 09:45 ET | 200 | 13.09 |
| 09:54 ET | 700 | 12.98 |
| 09:57 ET | 200 | 12.98 |
| 10:01 ET | 500 | 13.015 |
| 10:03 ET | 381 | 13.015 |
| 10:10 ET | 1526 | 12.94 |
| 10:12 ET | 2818 | 12.985 |
| 10:14 ET | 200 | 12.9 |
| 10:15 ET | 200 | 12.895 |
| 10:21 ET | 200 | 12.905 |
| 10:24 ET | 100 | 12.96 |
| 10:26 ET | 100 | 12.91 |
| 10:28 ET | 200 | 13.005 |
| 10:30 ET | 100 | 13.005 |
| 10:32 ET | 100 | 13.01 |
| 10:33 ET | 100 | 13.005 |
| 10:37 ET | 100 | 13.005 |
| 10:39 ET | 100 | 13.005 |
| 10:44 ET | 100 | 13.07 |
| 10:48 ET | 396 | 13.105 |
| 10:50 ET | 200 | 13.16 |
| 10:51 ET | 300 | 13.16 |
| 10:53 ET | 300 | 13.04 |
| 10:55 ET | 300 | 13.1 |
| 10:57 ET | 1163 | 13.02 |
| 11:00 ET | 3895 | 13.02 |
| 11:02 ET | 100 | 13.04 |
| 11:04 ET | 200 | 12.95 |
| 11:06 ET | 1060 | 12.935 |
| 11:11 ET | 264 | 12.915 |
| 11:13 ET | 600 | 12.91 |
| 11:15 ET | 1000 | 12.82 |
| 11:18 ET | 300 | 12.87 |
| 11:22 ET | 103 | 12.9199 |
| 11:29 ET | 100 | 12.86 |
| 11:31 ET | 100 | 12.89 |
| 11:33 ET | 100 | 12.9 |
| 11:38 ET | 200 | 12.91 |
| 11:40 ET | 362 | 12.9 |
| 11:42 ET | 300 | 12.86 |
| 11:44 ET | 100 | 12.88 |
| 11:45 ET | 436 | 12.905 |
| 11:47 ET | 100 | 12.895 |
| 11:51 ET | 400 | 12.885 |
| 11:54 ET | 1000 | 13 |
| 11:58 ET | 2346 | 12.98 |
| 12:00 ET | 100 | 13 |
| 12:02 ET | 800 | 13.01 |
| 12:03 ET | 200 | 13.01 |
| 12:05 ET | 300 | 13.01 |
| 12:09 ET | 700 | 13 |
| 12:16 ET | 1300 | 12.93 |
| 12:20 ET | 1827 | 12.945 |
| 12:25 ET | 449 | 12.945 |
| 12:30 ET | 400 | 12.945 |
| 12:32 ET | 1400 | 12.91 |
| 12:34 ET | 100 | 12.925 |
| 12:38 ET | 300 | 12.92 |
| 12:39 ET | 240 | 12.915 |
| 12:41 ET | 200 | 12.915 |
| 12:43 ET | 900 | 12.91 |
| 12:48 ET | 200 | 12.91 |
| 12:50 ET | 1700 | 12.91 |
| 12:52 ET | 1557 | 12.905 |
| 12:54 ET | 333 | 12.93 |
| 12:56 ET | 864 | 13 |
| 12:57 ET | 200 | 12.975 |
| 01:06 ET | 200 | 12.99 |
| 01:08 ET | 402 | 12.99 |
| 01:10 ET | 700 | 12.97 |
| 01:12 ET | 200 | 12.98 |
| 01:17 ET | 300 | 13 |
| 01:21 ET | 200 | 13.05 |
| 01:24 ET | 300 | 12.985 |
| 01:28 ET | 200 | 13.02 |
| 01:30 ET | 100 | 13.06 |
| 01:35 ET | 300 | 13.07 |
| 01:37 ET | 400 | 13.01 |
| 01:39 ET | 400 | 13 |
| 01:42 ET | 100 | 13 |
| 01:48 ET | 150 | 12.9901 |
| 01:51 ET | 100 | 13.03 |
| 01:53 ET | 200 | 13.025 |
| 01:55 ET | 500 | 13.005 |
| 02:02 ET | 200 | 12.995 |
| 02:04 ET | 426 | 12.99 |
| 02:06 ET | 231 | 12.99 |
| 02:09 ET | 452 | 13.01 |
| 02:15 ET | 100 | 13.01 |
| 02:20 ET | 500 | 12.98 |
| 02:22 ET | 100 | 12.98 |
| 02:24 ET | 100 | 12.985 |
| 02:26 ET | 300 | 12.97 |
| 02:27 ET | 832 | 12.9 |
| 02:31 ET | 500 | 12.9 |
| 02:33 ET | 599 | 12.87 |
| 02:36 ET | 202 | 12.86 |
| 02:38 ET | 500 | 12.83 |
| 02:40 ET | 300 | 12.83 |
| 02:42 ET | 500 | 12.85 |
| 02:45 ET | 100 | 12.87 |
| 02:47 ET | 3770 | 12.93 |
| 02:49 ET | 100 | 12.925 |
| 02:54 ET | 700 | 12.885 |
| 02:56 ET | 200 | 12.85 |
| 03:00 ET | 100 | 12.87 |
| 03:05 ET | 396 | 12.88 |
| 03:07 ET | 100 | 12.89 |
| 03:09 ET | 400 | 12.86 |
| 03:12 ET | 919 | 12.84 |
| 03:16 ET | 100 | 12.85 |
| 03:18 ET | 404 | 12.845 |
| 03:21 ET | 1606 | 12.83 |
| 03:23 ET | 200 | 12.81 |
| 03:25 ET | 400 | 12.79 |
| 03:27 ET | 500 | 12.79 |
| 03:34 ET | 1472 | 12.73 |
| 03:36 ET | 100 | 12.73 |
| 03:38 ET | 200 | 12.74 |
| 03:39 ET | 889 | 12.79 |
| 03:45 ET | 500 | 12.72 |
| 03:48 ET | 500 | 12.72 |
| 03:50 ET | 624 | 12.73 |
| 03:52 ET | 100 | 12.71 |
| 03:54 ET | 300 | 12.74 |
| 03:56 ET | 3848 | 12.89 |
| 03:57 ET | 7182 | 12.92 |
| 03:59 ET | 40457 | 12.95 |
Sep 10, 2024
DJ Y-mAbs Therapeutics Price Target Maintained With a $23.00/Share by Wedbush, from 9:11AM ET on Tuesday Sep 10, 2024 by Dow Jones
9:11AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 9, 2024
DJ Y-mAbs Therapeutics Price Target Maintained With a $20.00/Share by Cantor Fitzgerald, from 12:28PM ET on Monday Sep 09, 2024 by Dow Jones
12:28PM ET on Monday Sep 09, 2024 by Dow Jones
Sep 6, 2024
Sep 3, 2024
Y-mAbs to Participate in Upcoming Investor Conferences in September, from 8:32AM ET on Tuesday Sep 03, 2024 by Dow Jones
8:32AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 571.4M | -23.1x | --- |
Urogen Pharma Ltd | 537.0M | -3.9x | --- |
Regenxbio Inc | 527.8M | -2.0x | --- |
SAGE Therapeutics Inc | 437.7M | -1.0x | --- |
Alector Inc | 468.1M | -2.7x | --- |
Grail Inc | 422.3M | -0.1x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Treasurer
- Peter Pfreundschuh
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $571.4M |
|---|---|
Revenue (TTM) | $86.5M |
Shares Outstanding | 44.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.56 |
Book Value | $2.31 |
P/E Ratio | -23.1x |
Price/Sales (TTM) | 6.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -31.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
